Bio-Techne Corp

TECH•NASDAQ•HEALTHCAREMarket data unavailable

Price is syncing

Reported smart-money activity is still available below.

1 month

+3.0%

price return

Year to date

+5.5%

price return

Recent earnings

2/4

quarters beat

Big funds

8

hold this stock

News tone

Bullish

28 articles, 7 days

Smart money

Filed positions and reported activity tied to this stock.

8 funds hold a position and insiders have been net selling.

Real smart money

Funds holding this stock

8 holders

Combined position$1.7B

MC
Maverick Capital Ltd
Q1 2026 13F
$247.7M
position
DC
Durable Capital Partners LP
Q1 2026 13F
$232.9M
position
WR
Wallace R Weitz & Co
Q1 2026 13F
$34.1M
position
BC
Baron Capital
Q1 2026 13F
$29.3M
position
P
Point72
Steven Cohen · Q1 2026 13F
$15.4M
position

Show all 8 holders

B
BlackRock
Q1 2026 13F
$640.9M
position
FL
FMR LLC
Q1 2026 13F
$412.9M
position
JC

Insiders

What insiders are doing

1 trade · 6 mo

Sold$320K

Sells (1)

HA
Herr Amy E.
Dir · May 12
$320K
sold

Checking federal contract awards

Coverage gaps for TECHNo recent market-voice mention

News

Recent coverage and its overall tone.

News

What the news says

28 articles · 7 days

Coverage is bullish

16 bullish · 12 neutral · 0 bearish

Tone of tracked coverage

Bio-Techne Corp (TECH) Earnings Forecast: Future EPS & Revenue Growth Estimates
NeutralJul 27
TECH|Bio-Techne Corp|Price:71.600|Chg%:-0.170
NeutralJul 27
TECH|Bio-Techne Corp|Price:71.600|Chg%:-0.170
NeutralJul 26
Bio-Techne Corp (TECH) Institutional Confidence
Leans bullishJul 25
Bio-Techne Corp Revenue Breakdown – NASDAQ:TECH
NeutralJul 25
Charles River Laboratories International Inc. Stock Advances 4.8%, Outperforms Peers
Leans bullishJul 23
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business
Leans bullishJul 22
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business
Leans bullishJul 22

JPMorgan Chase

Q1 2026 13F

$53.3M

position